Developer docs
API playgroundTry for free, no card

Search company profiles

Proscia

Full company profile

uuid00002tx

Namestring
Proscia
Legal namestring
Proscia Inc.
Websiteurl
proscia.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, pathology AI platform, computational pathology, biomarker discovery software, companion diagnostics platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Pathology Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Enterprise SaaS subscriptions (Concentriq platform)
TypeSubscription Recurring
Description

Recurring subscription revenue from Concentriq AP, AP-Dx, and Concentriq LS deployed at diagnostic laboratories, academic medical centers, health systems, CROs, and biopharmaceutical companies. Cloud-native SaaS pricing is quote-based and not publicly disclosed. Customers include 16 of the top 20 pharma companies and 4,000+ hospitals/clinics globally.

proscia.com
2Professional services and implementation
TypeProfessional Services
Description

Tailored implementations delivered by Proscia's Professional Services team: deployment architecture, image and data migration, scanner/LIS integration, and workflow redesign. Includes 24/7 support, expert clinical/operational consulting, and bespoke onboarding plans for enterprise customers.

proscia.com
3Real-world data and biopharma partnerships
TypeData Monetisation
Description

Revenue from enabling laboratories to share de-identified real-world data with biopharma partners on Concentriq (Aperture network) — including clinical trial matching, companion diagnostic development, and biomarker validation programs. PathGroup cited >$1M new revenue from existing case volume using Concentriq.

proscia.com
4AI application and platform marketplace revenue
TypeManaged Services
Description

Concentriq Compute managed AI deployment service, and AI companion diagnostic commercialization with revenue-share arrangements enabling precision medicine organizations to co-develop and monetize AI products alongside Proscia.

proscia.com
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise quote-based SaaS — Concentriq demo and custom pricing per workflow
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Customers schedule a 30-minute demo with a Proscia expert to scope a working session and receive custom pricing tailored to their workflows.

proscia.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Concentriq
Description

Pathology AI platform (portfolio including Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) — the company's flagship product brand.

proscia.com
+4 more records
Core offering1 text field

Proscia develops and sells Concentriq, an enterprise pathology AI platform that enables laboratories, health systems, academic medical centers, contract research organizations (CROs), and biopharmaceutical companies to manage, analyze, and derive insights from whole-slide pathology images and associated clinical, molecular, and genomic data. The platform is offered in distinct configurations (Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) and is delivered as cloud-native SaaS with integrations to scanners, LIS systems, and 230+ interoperable AI applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Proscia's offering is a single underlying pathology AI platform branded Concentriq, delivered as a portfolio of distinct configurations rather than separate products. Concentriq AP-Dx is FDA 510(k)-cleared in the U.S. (with the Hamamatsu NanoZoomer S360MD Slide scanner), CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK for primary clinical diagnosis, while Concentriq AP and Concentriq LS are Research Use Only products for prospective workflows and life sciences research. The latest release, Concentriq Fifth Generation, layers an AI-native architecture with frontier vision, language, and multimodal models across all configurations. Sitting on top of this platform are two adjacent offerings: Proscia Aperture, a real-world multimodal data network that connects Concentriq to cohorts of AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics, and Concentriq Compute, a fully managed compute service for deploying customer AI models alongside Concentriq data. Together, these products support biomarker discovery, clinical development, companion diagnostics, and case review, and are used by 16 of the top 20 pharmaceutical companies and over 4,000 hospitals and clinics globally.

Product and service7 records
1Concentriq (platform)
CategoryPathology AI Platform
Description

Enterprise pathology AI platform that powers precision medicine from discovery through diagnosis with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review. The Concentriq portfolio is a single underlying platform offered in distinct configurations.

2Concentriq AP-Dx
CategoryClinical Diagnostic Software
Description

Regulatory-cleared configuration of the Concentriq platform for primary clinical diagnosis. FDA 510(k)-cleared in the U.S., CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK. Built on the same technology as Concentriq AP but cleared for diagnostic use.

3Concentriq AP
CategoryResearch Pathology Software
Description

Research Use Only configuration of the Concentriq platform; powers Proscia's interoperable AI applications and native AI features for research workflows. Not for use in diagnostic procedures.

4Concentriq LS
CategoryLife Sciences Research Software
Description

Life sciences configuration of the Concentriq platform for biomarker discovery, clinical development, and companion diagnostics workflows. For Research Use Only; not for use in diagnostic procedures.

5Concentriq Fifth Generation
CategoryAI Pathology Platform
Description

Latest generation of the Concentriq platform built on a new AI-native architecture with frontier vision, language, and multimodal models at the core. Introduces unified intelligence across images, metadata, and clinical/scientific context for biomarker discovery, clinical development, companion diagnostics, and case review.

6Proscia Aperture
CategoryReal-World Data Network
Description

Real-world multimodal data network that brings AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics into Concentriq as cohorts or real-time insights, enabling validation against real-world variation and supporting biomarker discovery.

7Concentriq Compute
CategoryManaged AI Compute Service
Description

Fully managed compute service that takes AI models from ready to running in days with no infrastructure to stand up and with IP retained by the customer; executes containerized model workloads right beside Concentriq data.

Scale indicator28 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-for-biotech company applying multimodal AI to pathology and clinical data, with biopharma R&D and CDx partnerships. Comparable to Proscia in the biopharma/AI-for-pathology overlap, though more research-oriented than clinical-platform focused.

TypeDirect peer
Description

AI pathology company with FDA-authorized cancer detection products and enterprise deployments across healthcare and life sciences. Comparable to Proscia as a direct competitor in clinical AI pathology and biopharma biomarker programs.

TypeBroad incumbent
Description

Enterprise digital pathology platform from a large diversified medtech incumbent, with scanner, viewer, and workflow components. Comparable to Proscia as a broad incumbent competitor in primary-diagnosis digital pathology deployments.

TypeDirect peer
Description

AI image analysis vendor whose applications run natively inside the Concentriq viewer. Directly comparable as a peer/partner providing biomarker quantification (e.g., PD-L1, HER2, Ki-67) in clinical pathology workflows.

TypeDirect peer
Description

Digital pathology software vendor (HALO platform) used widely in pharma and academic research for whole-slide image analysis. Comparable to Proscia as a direct competitor in life-sciences pathology software and AI-driven image analysis.

TypeDirect peer
Description

AI-native digital pathology platform serving both biopharma and clinical diagnostics with proprietary foundation models. Directly comparable to Proscia across pharma biomarker discovery, AI-based CDx, and clinical pathology deployments.

TypeDirect peer
Description

AI-powered cancer diagnostics platform (Galen) deployed in clinical pathology workflows and also interoperable with Proscia via the Ready partner program. Directly comparable as an AI pathology vendor serving clinical labs and reference labs.

TypeDirect peer
Description

AI-powered image analysis platform for pathology, integrated with Proscia Concentriq via a 2026 non-exclusive partnership. Comparable as a direct competitor/partner offering AI diagnostic applications for clinical and research pathology.

TypeDirect peer
Description

Quantitative digital pathology and AI image analysis platform interoperable with Concentriq. Directly comparable as a peer/partner providing biomarker quantification and AI scoring for clinical and translational pathology workflows.

TypeBroad incumbent
Description

Broad incumbent in anatomic pathology combining slide scanners, staining reagents, and the uPath enterprise software platform. Comparable to Proscia as a major competitor in primary-diagnosis digital pathology, with a much larger installed base in clinical labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers23 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration12 records

Each record includes

Title, Type, Description, Source

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proscia

Digital Pathology Softwareproscia.com

Proscia firmographics

Firmographics
Name
Proscia
Legal name
Proscia Inc.
Website
https://proscia.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Proscia industry classification

Industry
Product category
Digital Pathology Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Digital pathology software
  • Pathology AI platform
  • Computational pathology
  • Biomarker discovery software
  • Companion diagnostics platform

Where Proscia is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Proscia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Enterprise SaaS subscriptions (Concentriq platform): Recurring subscription revenue from Concentriq AP, AP-Dx, and Concentriq LS deployed at diagnostic laboratories, academic medical centers, health systems, CROs, and biopharmaceutical companies. Cloud-native SaaS pricing is quote-based and not publicly disclosed. Customers include 16 of the top 20 pharma companies and 4,000+ hospitals/clinics globally.
  2. Professional services and implementation: Tailored implementations delivered by Proscia's Professional Services team: deployment architecture, image and data migration, scanner/LIS integration, and workflow redesign. Includes 24/7 support, expert clinical/operational consulting, and bespoke onboarding plans for enterprise customers.
  3. Real-world data and biopharma partnerships: Revenue from enabling laboratories to share de-identified real-world data with biopharma partners on Concentriq (Aperture network) — including clinical trial matching, companion diagnostic development, and biomarker validation programs. PathGroup cited >$1M new revenue from existing case volume using Concentriq.
  4. AI application and platform marketplace revenue: Concentriq Compute managed AI deployment service, and AI companion diagnostic commercialization with revenue-share arrangements enabling precision medicine organizations to co-develop and monetize AI products alongside Proscia.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise quote-based SaaS — Concentriq demo and custom pricing per workflow

Go-to-market motion3 records

Distribution channels5 records

Marketing channels12 records

Proscia product offering

Product offering

Core offering

Proscia develops and sells Concentriq, an enterprise pathology AI platform that enables laboratories, health systems, academic medical centers, contract research organizations (CROs), and biopharmaceutical companies to manage, analyze, and derive insights from whole-slide pathology images and associated clinical, molecular, and genomic data. The platform is offered in distinct configurations (Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) and is delivered as cloud-native SaaS with integrations to scanners, LIS systems, and 230+ interoperable AI applications.

Product overview

Proscia's offering is a single underlying pathology AI platform branded Concentriq, delivered as a portfolio of distinct configurations rather than separate products. Concentriq AP-Dx is FDA 510(k)-cleared in the U.S. (with the Hamamatsu NanoZoomer S360MD Slide scanner), CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK for primary clinical diagnosis, while Concentriq AP and Concentriq LS are Research Use Only products for prospective workflows and life sciences research. The latest release, Concentriq Fifth Generation, layers an AI-native architecture with frontier vision, language, and multimodal models across all configurations. Sitting on top of this platform are two adjacent offerings: Proscia Aperture, a real-world multimodal data network that connects Concentriq to cohorts of AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics, and Concentriq Compute, a fully managed compute service for deploying customer AI models alongside Concentriq data. Together, these products support biomarker discovery, clinical development, companion diagnostics, and case review, and are used by 16 of the top 20 pharmaceutical companies and over 4,000 hospitals and clinics globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Concentriq: Pathology AI platform (portfolio including Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) — the company's flagship product brand.
  • Concentriq AP-Dx
  • Concentriq AP
  • Concentriq LS
  • Proscia Aperture

Products and services

  • Concentriq (platform) Enterprise pathology AI platform that powers precision medicine from discovery through diagnosis with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review. The Concentriq portfolio is a single underlying platform offered in distinct configurations.
  • Concentriq AP-Dx Regulatory-cleared configuration of the Concentriq platform for primary clinical diagnosis. FDA 510(k)-cleared in the U.S., CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK. Built on the same technology as Concentriq AP but cleared for diagnostic use.
  • Concentriq AP Research Use Only configuration of the Concentriq platform; powers Proscia's interoperable AI applications and native AI features for research workflows. Not for use in diagnostic procedures.
  • Concentriq LS Life sciences configuration of the Concentriq platform for biomarker discovery, clinical development, and companion diagnostics workflows. For Research Use Only; not for use in diagnostic procedures.
  • Concentriq Fifth Generation Latest generation of the Concentriq platform built on a new AI-native architecture with frontier vision, language, and multimodal models at the core. Introduces unified intelligence across images, metadata, and clinical/scientific context for biomarker discovery, clinical development, companion diagnostics, and case review.
  • Proscia Aperture Real-world multimodal data network that brings AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics into Concentriq as cohorts or real-time insights, enabling validation against real-world variation and supporting biomarker discovery.
  • Concentriq Compute Fully managed compute service that takes AI models from ready to running in days with no infrastructure to stand up and with IP retained by the customer; executes containerized model workloads right beside Concentriq data.

Companies that use Proscia

Customer profile

Named customers23 records

Segments5 records

Ideal customer profiles4 records

Proscia technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability12 records

Feature9 records

Proscia partnerships and signals

Strategic signal

Scale indicators28 records

Recent moves6 records

Expansion highlights6 records

Proscia competitors and assessment

Company assessment

Emerging players

  • Owkin: AI-for-biotech company applying multimodal AI to pathology and clinical data, with biopharma R&D and CDx partnerships. Comparable to Proscia in the biopharma/AI-for-pathology overlap, though more research-oriented than clinical-platform focused.

Direct peers

  • Paige: AI pathology company with FDA-authorized cancer detection products and enterprise deployments across healthcare and life sciences. Comparable to Proscia as a direct competitor in clinical AI pathology and biopharma biomarker programs.
  • Mindpeak: AI image analysis vendor whose applications run natively inside the Concentriq viewer. Directly comparable as a peer/partner providing biomarker quantification (e.g., PD-L1, HER2, Ki-67) in clinical pathology workflows.
  • Indica Labs: Digital pathology software vendor (HALO platform) used widely in pharma and academic research for whole-slide image analysis. Comparable to Proscia as a direct competitor in life-sciences pathology software and AI-driven image analysis.
  • PathAI: AI-native digital pathology platform serving both biopharma and clinical diagnostics with proprietary foundation models. Directly comparable to Proscia across pharma biomarker discovery, AI-based CDx, and clinical pathology deployments.
  • Ibex Medical Analytics: AI-powered cancer diagnostics platform (Galen) deployed in clinical pathology workflows and also interoperable with Proscia via the Ready partner program. Directly comparable as an AI pathology vendor serving clinical labs and reference labs.
  • Aiforia Technologies: AI-powered image analysis platform for pathology, integrated with Proscia Concentriq via a 2026 non-exclusive partnership. Comparable as a direct competitor/partner offering AI diagnostic applications for clinical and research pathology.
  • Visiopharm: Quantitative digital pathology and AI image analysis platform interoperable with Concentriq. Directly comparable as a peer/partner providing biomarker quantification and AI scoring for clinical and translational pathology workflows.

Broad incumbents

  • Philips Digital Pathology (IntelliSite Pathology Solution): Enterprise digital pathology platform from a large diversified medtech incumbent, with scanner, viewer, and workflow components. Comparable to Proscia as a broad incumbent competitor in primary-diagnosis digital pathology deployments.
  • Roche Digital Pathology (VENTANA / uPath): Broad incumbent in anatomic pathology combining slide scanners, staining reagents, and the uPath enterprise software platform. Comparable to Proscia as a major competitor in primary-diagnosis digital pathology, with a much larger installed base in clinical labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

Proscia social profiles

Digital presence

Proscia compliance and trust

Trust signal

Compliance8 records

Proscia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proscia leadership team

Management profile

Number of profiles

Profiles5 records

Proscia funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proscia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proscia

What does Proscia do?

Proscia develops and sells Concentriq, an enterprise pathology AI platform that enables laboratories, health systems, academic medical centers, contract research organizations (CROs), and biopharmaceutical companies to manage, analyze, and derive insights from whole-slide pathology images and associated clinical, molecular, and genomic data. The platform is offered in distinct configurations (Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) and is delivered as cloud-native SaaS with integrations to scanners, LIS systems, and 230+ interoperable AI applications.

Is Proscia a public or private company?

Proscia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Proscia founded?

Proscia was founded in 2014. It employs 101 to 250 people.

Where is Proscia based?

Proscia is headquartered in Philadelphia, United States, in the North America region.

How does Proscia make money?

Four revenue lines are on record. Enterprise SaaS subscriptions (Concentriq platform) is the primary driver. The others are professional services and implementation, real-world data and biopharma partnerships and AI application and platform marketplace revenue.

Who are Proscia's main competitors?

Owkin is listed as an emerging player. Direct peers are Paige, Mindpeak, Indica Labs, PathAI, Ibex Medical Analytics, Aiforia Technologies and Visiopharm. Broad incumbents are Philips Digital Pathology (IntelliSite Pathology Solution) and Roche Digital Pathology (VENTANA / uPath).

Does Proscia have an API?

Yes. Proscia offers open APIs including REST API, Custom APIs, SDK, and Model Context Protocol (MCP). Image analysis models integrate through an API that posts results back as overlays, heatmaps, and structured values that display consistently to users in the Concentriq viewer. Every Concentriq service is an open API, enabling models and agents built by teams to plug in without a new integration each time. Concentriq Compute is a fully managed compute service for running AI models as containerized workloads beside data, with embeddings from frontier pathology models exposed via API. Analysis API enables programmatic model execution. Data stays accessible and portable through APIs and MCP, running on storage built for scale.

What industry is Proscia in?

Proscia's product category is Digital Pathology Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerAgilent completes Proscia acquisitionAgilent completed its acquisition of Proscia for $240 million in cash, with up to $30 million more tied to performance milestones. Proscia's vendor-agnostic digital-pathology platform, cleared for primary diagnosis, joins Agilent's Life Sciences and Diagnostics Markets Group. The deal adds recurring software revenue and AI-enabled pathology tools.The future of tradingAgilent Completes Acquisition of ProsciaAgilent completed its acquisition of digital pathology software provider Proscia for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. The deal adds a recurring-revenue software business to Agilent's pathology portfolio, combining instrumentation and reagents with Proscia's platform for AI-enabled diagnostics and drug discovery.Business Wire BlogAgilent Completes Acquisition of ProsciaAgilent Technologies completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash at closing, with up to $30 million more payable based on future performance milestones. The deal adds Proscia's vendor-agnostic platform with FDA 510(k) clearance to Agilent's pathology portfolio, expanding its ability to support AI-enabled workflows and companion-diagnostics.Stock TitanAgilent completes $240M acquisition of ProsciaAgilent completed its acquisition of Proscia for $240 million in cash, with up to $30 million more payable on performance milestones. The deal adds Proscia's FDA-cleared digital-pathology platform and recurring software revenue to Agilent's portfolio. Proscia will join Agilent's Life Sciences and Diagnostics Markets Group.TradingViewAgilent Technologies Inc. (A) Completes Proscia Acquisition for $240M CashAgilent completed its acquisition of Proscia for $240M cash, with up to $30M additional payable based on future performance milestones. The deal adds recurring-revenue software to Agilent's portfolio, but no revenue or earnings contribution was disclosed.TradingViewAgilent Completes Acquisition of ProsciaAgilent completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash at closing, with up to $30 million more payable on future performance milestones. The deal adds Proscia's vendor-agnostic platform with FDA 510(k) clearance to Agilent's pathology portfolio, expanding its AI-enabled workflows and companion-diagnostics capabilities.TechnicalProscia’s bet on Philly talent pays off in a $240M Agilent buyoutProscia, a digital pathology company, agreed to be acquired by Agilent Technologies for $240 million in cash, with up to $30 million more if milestones are met. The deal, closing in fiscal 2027, combines Proscia's software with Agilent's lab instruments. The acquisition aims to merge products and market presence, not just talent.Pulse 2.0Agilent To Acquire Proscia For Up To $270 Million To Expand AI-Enabled Digital PathologyAgilent agreed to acquire Proscia, a digital pathology software provider, in an all-cash deal valued at $240 million at closing plus up to $30 million tied to performance milestones. Proscia serves over 4,000 laboratories and 16 of the world's 20 largest pharmaceutical companies, generating more than $18 million in revenue. The acquisition is expected to close early in Agilent's fiscal year 2027.Medical Device NetworkAgilent acquires Proscia in deal worth up to $270mAgilent agreed to acquire digital pathology provider Proscia in an all-cash deal worth up to $270m, paying $240m upfront with up to $30m contingent on performance milestones. The acquisition, expected to close in fiscal 2027, aims to strengthen Agilent's pathology portfolio and integrate Proscia's Concentriq Dx platform with its existing diagnostics.Digital Health NewsAgilent to Acquire Proscia for Up to $270 Mn to Expand AI-Enabled Digital PathologyAgilent agreed to acquire Proscia, a digital pathology software provider, for up to $270 million in an all-cash deal. The acquisition combines Agilent's pathology instrumentation with Proscia's software, adding recurring revenue and AI-enabled synergies. Closing is expected early in Agilent's fiscal year 2027.